Literature DB >> 27357174

Curative treatment of head and neck squamous cell carcinoma : Organ preservation strategies in clinical routine in German-speaking countries.

T Kurzweg1, J Kimmeyer2, R Knecht3, T K Hoffmann2, C-J Busch3, B B Lörincz3, P J Schuler2, S Laban2.   

Abstract

INTRODUCTION: For the treatment of head and neck squamous cell carcinoma (HNSCC), there are currently no official standard of care guidelines in German-speaking countries, with the exception of oral cavity cancer. In order to learn about the applied treatment modalities in the clinical routine, we conducted a web-based survey to evaluate the local standards of palliative and curative treatment of HNSCC. This article focuses on the curative treatment options and organ preservation strategies.
MATERIALS AND METHODS: The survey consisted of a web-based questionnaire that was performed between November 2013 and July 2014. The questionnaire included ten multiple-choice questions and four open questions in the section about curative treatment.
RESULTS: Altogether, 62 of the 204 addressed centers participated in the survey. For primary chemoradiation (CRT), most centers used a platinum-based chemotherapy (52/54, 96.3 %). Induction chemotherapy (ICT) was offered in 37 of the 62 centers (60 %). In oral cavity cancer, CRT and ICT were used in 37.5 and 4.3 % of the cases, respectively. In oropharyngeal cancer, CRT and ICT were applied in 44.5 and 10.3 % of cases, respectively. For hypopharyngeal cancer, 44.8 % of the patients received CRT and 11.8 % received ICT, while for laryngeal cancer 35.9 % received CRT and 9.4 % underwent ICT.
CONCLUSION: Our data showed that a variety of treatments are used for HNSCC within German-speaking countries. Many centers offer ICT. The majority of the hospitals uses platinum-based therapy as a conservative first-line option in their organ preservation protocols.

Entities:  

Keywords:  Chemoradiotherapy; Laryngeal cancer; Oral cavity; Pharyngeal cancer; Questionnaire

Mesh:

Substances:

Year:  2016        PMID: 27357174     DOI: 10.1007/s00106-016-0191-1

Source DB:  PubMed          Journal:  HNO        ISSN: 0017-6192            Impact factor:   1.284


  27 in total

1.  Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial.

Authors:  Robert Haddad; Anne O'Neill; Guilherme Rabinowits; Roy Tishler; Fadlo Khuri; Douglas Adkins; Joseph Clark; Nicholas Sarlis; Jochen Lorch; Jonathan J Beitler; Sewanti Limaye; Sarah Riley; Marshall Posner
Journal:  Lancet Oncol       Date:  2013-02-13       Impact factor: 41.316

2.  Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer.

Authors:  Ezra E W Cohen; Theodore G Karrison; Masha Kocherginsky; Jeffrey Mueller; Robyn Egan; Chao H Huang; Bruce E Brockstein; Mark B Agulnik; Bharat B Mittal; Furhan Yunus; Sandeep Samant; Luis E Raez; Ranee Mehra; Priya Kumar; Frank Ondrey; Patrice Marchand; Bettina Braegas; Tanguy Y Seiwert; Victoria M Villaflor; Daniel J Haraf; Everett E Vokes
Journal:  J Clin Oncol       Date:  2014-07-21       Impact factor: 44.544

3.  Early prediction of survival following induction chemotherapy with DCF (docetaxel, cisplatin, 5-fluorouracil) using FDG PET/CT imaging in patients with locally advanced head and neck squamous cell carcinoma.

Authors:  Ronan Abgral; Pierre-Yves Le Roux; Nathalie Keromnes; Jean Rousset; Gérald Valette; Dominique Gouders; Cyril Leleu; Delphine Mollon; Emmanuel Nowak; Solène Querellou; Pierre-Yves Salaün
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-08-16       Impact factor: 9.236

4.  Single-cycle induction chemotherapy followed by chemoradiotherapy or surgery in patients with head and neck cancer: what are the best predictors of remission and prognosis?

Authors:  Sabine Semrau; Marlen Haderlein; Daniela Schmidt; Michael Lell; Walburga Wolf; Frank Waldfahrer; Michael Uder; Heinrich Iro; Torsten Kuwert; Rainer Fietkau
Journal:  Cancer       Date:  2014-12-23       Impact factor: 6.860

5.  Results of chemoselection with short induction chemotherapy followed by chemoradiation or surgery in the treatment of functionally inoperable carcinomas of the pharynx and larynx.

Authors:  Sabine Semrau; Daniela Schmidt; Michael Lell; Frank Waldfahrer; Sebstian Lettmaier; Torsten Kuwert; Heinrich Iro; Rainer Fietkau
Journal:  Oral Oncol       Date:  2013-01-12       Impact factor: 5.337

6.  Preliminary results of Radiation Therapy Oncology Group 97-03: a randomized phase ii trial of concurrent radiation and chemotherapy for advanced squamous cell carcinomas of the head and neck.

Authors:  A S Garden; J Harris; E E Vokes; A A Forastiere; J A Ridge; C Jones; E M Horwitz; B S Glisson; L Nabell; J S Cooper; W Demas; E Gore
Journal:  J Clin Oncol       Date:  2004-07-15       Impact factor: 44.544

7.  Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients.

Authors:  Jean-Pierre Pignon; Aurélie le Maître; Emilie Maillard; Jean Bourhis
Journal:  Radiother Oncol       Date:  2009-05-14       Impact factor: 6.280

8.  Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012.

Authors:  J Ferlay; E Steliarova-Foucher; J Lortet-Tieulent; S Rosso; J W W Coebergh; H Comber; D Forman; F Bray
Journal:  Eur J Cancer       Date:  2013-02-26       Impact factor: 9.162

9.  Randomized comparison of neoadjuvant cisplatin and fluorouracil infusion followed by radiation versus concomitant treatment in advanced head and neck cancer.

Authors:  S G Taylor; A K Murthy; J M Vannetzel; P Colin; M Dray; D D Caldarelli; S Shott; E Vokes; J L Showel; J C Hutchinson
Journal:  J Clin Oncol       Date:  1994-02       Impact factor: 44.544

10.  Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer.

Authors:  Arlene A Forastiere; Qiang Zhang; Randal S Weber; Moshe H Maor; Helmuth Goepfert; Thomas F Pajak; William Morrison; Bonnie Glisson; Andy Trotti; John A Ridge; Wade Thorstad; Henry Wagner; John F Ensley; Jay S Cooper
Journal:  J Clin Oncol       Date:  2012-11-26       Impact factor: 44.544

View more
  1 in total

1.  Comparative effectiveness trial of transoral head and neck surgery followed by adjuvant radio(chemo)therapy versus primary radiochemotherapy for oropharyngeal cancer (TopROC).

Authors:  Lara Bußmann; Simon Laban; Claus Wittekindt; Carmen Stromberger; Silke Tribius; Nikolaus Möckelmann; Arne Böttcher; Christian Stephan Betz; Jens Peter Klussmann; Volker Budach; Adrian Muenscher; Chia-Jung Busch
Journal:  BMC Cancer       Date:  2020-07-29       Impact factor: 4.430

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.